N/A
N=50
A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic Lobectomies
Non-Small Cell Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT03056300 ↗Enrolled (actual)
50
Serious AEs
10.0%
Results posted
Dec 2018
Primary outcome: Primary: Incidence of Intra-Operative Hemostatic Interventions — 1.8 Percentage of vessel transections
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ethicon, Inc.
- Primary completion
- May 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Intra-Operative Hemostatic Interventions |
1.8 | — |
| PRIMARY Post-operative Interventions or Procedures Related to Pulmonary Artery or Pulmonary Vein Bleeding |
— | — |
Summary
The primary objective of this trial is to demonstrate the effectiveness of the powered vascular stapler for transection of the pulmonary artery (PA) and pulmonary vein (PV) during Video-Assisted Thoracoscopic Lobectomy.
Eligibility Criteria
Inclusion Criteria
- Subjects with a confirmed or suspected diagnosis of stage IA to stage IIB non-small cell lung cancer scheduled for lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,7th Edition)7;
- Subjects scheduled for VATS lobectomy in accordance with their institution's SOC;
- Performance status 0-1 (Eastern Cooperative Oncology Group classification);
- ASA score < 3;
- No prior history of VATS or open lung surgery (on the lung in which the procedure will be performed);
- Willing to give consent and comply with study-related evaluation and treatment schedule; and
- 18-75 years of age (inclusive).
Exclusion Criteria
- Active (subject currently receiving systemic treatment) bacterial infection or fungal infection;
- Systemic administration (intravenous or oral) of steroids, including herbal supplements that contain steroids (within 30 days prior to study procedure);
- Uncontrolled diabetes mellitus;
- End stage renal or liver disease;
- History of severe cardiovascular disease;
- FEV1% <50% or severe COPD;
- Prior chemotherapy or radiation for lung cancer;
- Scheduled concurrent surgical procedure other than diagnostic wedge resection followed by lobectomy (central venous access - e.g., port placement, mediastinoscopy with lymph node sampling, and VATS lymphadenectomy are allowed);
- Robotic-assisted procedure;
- Women who are pregnant or lactating at the time of screening;
- Physical or psychological condition which would impair study participation;
- The subject is judged unsuitable for study participation by the Investigator for any other reason;
- Participation in any other investigational drug (within 30 days or 5 half-lives of an investigational drug) or device study; or
- Unable or unwilling to attend follow-up visits and examinations.
Data sourced from ClinicalTrials.gov (NCT03056300). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.